Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2

This study has been completed.
Information provided by:
Danish Headache Center Identifier:
First received: November 22, 2005
Last updated: July 31, 2006
Last verified: November 2005

The aim of the present study is to explore functional consequences of migraine gene mutations on their responses to GTN infusion.

Condition Intervention
Familial Hemiplegic Migraine Type 1 and 2
Healthy Volunteers
Drug: GTN

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Educational/Counseling/Training
Official Title: Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2

Resource links provided by NLM:

Further study details as provided by Danish Headache Center:

Primary Outcome Measures:
  • headache and associated symptoms , blood flow velocity of the middle cerebral artery, diameter of the superficial temporal artery

Secondary Outcome Measures:
  • MAP, HR

Estimated Enrollment: 30
Study Start Date: April 2005
Estimated Study Completion Date: March 2006
Detailed Description:

Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks in approximately 80% of migraine sufferers. After systemic administration GTN is transformed to nitric oxide (NO). Treatment of spontaneous migraine attacks with an inhibitor of NO is effective in 60% of patients. These data show that NO is involved in both initiation and maintenance of migraine attack.

The consequence of migraine gene mutations on relevant migraine pathways has never been tested. The aim of the present study is to explore functional consequences of migraine gene mutations on their responses to GTN infusion. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Patients: Diagnosis of familial hemiplegic migraine (IHS-classification criteria) caused by mutations in the CACNA1A gene and the ATP1A2 gene.

Controls: healthy volunteers

Exclusion Criteria:

Controls: No primary headache in their own history

Patients and controls:

  • A history of cerebrovascular disease and other CNS- disease
  • A history of serious somatic and mental disease
  • A history suggesting ischaemic heart disease
  • A history of hypo- or hypertension
  • Daily intake of medication apart from oral contraceptives
  • Abuse of alcohol or medicine (opioid analgesics).
  • Pregnant or breastfeeding women.

On the study day:

  • No intake of a simple analgesic in the previous 48 hours
  • No headache in the previous 48 hours
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00257985

Danish Headache Center, University of Copenhagen, Department of Neurology, Glostrup Hospital
Glostrup, Copenhagen, Denmark, DK-2600
Sponsors and Collaborators
Danish Headache Center
Principal Investigator: Jakob Møller Hansen, MD Danish Headache Center
  More Information

No publications provided Identifier: NCT00257985     History of Changes
Other Study ID Numbers: FHM-GTN 2005
Study First Received: November 22, 2005
Last Updated: July 31, 2006
Health Authority: Denmark: Den Centrale Videnskabsetiske Komité

Keywords provided by Danish Headache Center:
Familial hemiplegic migraine type 1 and 2
middle cerebral artery
superficial temporal artery

Additional relevant MeSH terms:
Migraine Disorders
Migraine with Aura
Brain Diseases
Central Nervous System Diseases
Headache Disorders
Headache Disorders, Primary
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Cardiovascular Agents
Pharmacologic Actions
Therapeutic Uses
Vasodilator Agents processed this record on February 25, 2015